Deerfield Management United States

Industry

Investment Management

Specialties

Investment, Information, Philanthropy, Healthcare

We seek to advance healthcare through investment, information and philanthropy. At Deerfield, we owe our success to our team-oriented process, which brings together many decades of experience, across all sub-sectors of healthcare, to deliver our clients with the best funding solutions possible. 

We are a non-activist, relationship-focused firm who is proud to help the companies we invest in, because we see their potential to advance healthcare and drive change in this crucial industry.

Steve Hochberg
Partner 

Defined Health United States

Defined Health advises senior management at Life Sciences clients on the value of compounds  and technology platforms in development, from pre-IND to indication prioritization and sequencing,, repurposing, reformulation, and life cycle management. Our scientifically trained consultants leverage the firm's 30 years of experience with evaluations that are grounded in the science, and informed by an unparalleled understanding of current and evolving clinical practices, development and regulatory issues, competitive commercial dynamics and pricing, reimbursement and market access practices. 

In addition to our core Opportunity Assessment business, we have a large Search & Evaluation practice, wherein we identify and assess relevant opportunities for therapeutic area expansion, as well as a Strategy practice that addresses broader corporate development initiatives -- therapeutic and disease area and market entry strategies.

Our clients include 13 of the top 20 pharmacos, 6 of the top 10 large cap biotechs, and scores of specialty pharma and pre-commercial biotech companies, as well as several royalty investors and two of the top private equity firms.  We are proud to have an 80% repeat and referral client base.

Find out more about Defined Health and view our recent presentations on topical and therapeutic area specific subjects at www.definedhealth.com.


Ginny Llobell
Vice President 
David Lomb, PhD
Senior Consultant 

Desmond Heath United States

Dr DESMOND HEATH
Clinical Instructor 

DiamondRock Capital United States

DiamondRock, a lodging-focused MD corporation operates as a real estate investment trust (REIT), owns a portfolio of 29 premium hotels & resorts containing ~10,900 rooms, concentrated in key gateway cities and destination resorts throughout North America and the U.S.V.I. Our vision is to be the premier allocator of capital in the lodging industry and our goal is to deliver above-average shareholder returns across the full lodging cycle. We strive to differentiate ourselves from peers by executing on three strategic principles: 

- Maintaining a balanced portfolio of high-quality assets with superior growth prospects in markets that have high barriers to entry. 
- Employing disciplined and innovative approaches to asset management that drive meaningful upside to underlying performance. 
- Preserving a clean, conservative balance sheet that supports strategic and financial flexibility, dividends and shareholder returns. 

As an owner, as opposed to an operator, we receive all operating profits or losses generated by our hotels after we pay fees to the hotel managers, which are based on the revenues & profitability of the hotels. Each of our 29 hotels & resorts is managed by a third party. Most are operated under a brand owned by one of the leading global lodging companies: Marriott International, Inc.™, Starwood Hotels & Resorts Worldwide, Inc.™, or Hilton Worldwide™. 

We regularly analyze all of the properties in our portfolio, as well as market conditions, to ensure that we are allocating capital to the highest return opportunities. Our ongoing capital allocation activities include renovation projects, marketing non-core assets for sale & acquisitions. Additionally, our conservative capital structure helps us achieve the optimal balance between value, risk and cost of capital. We seek to further enhance value through efficient corporate overhead, best-in-class corporate governance practices, and openness and transparency in our communications with investors.

Website:
http://drhc.com
Mr Neil Rock
Founder and Managing Partner  

E Squared Capital United States

Ms Trammy Lai
Healthcare Analyst 

Enumeral Biomedical Corp United States

Enumeral Biomedical Holdings, Inc. is a Biotechnology company located at 200 CambridgePark Drive, Cambridge, Massachusetts 02140 United States 

Enumeral is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells. Our unique platform allows us to identify and characterize promising new drugs relevant to cancer, infectious and inflammatory diseases, giving us the potential to positively affect millions of patients who are underserved by current therapeutic alternatives.

Mr Derek Brand
VP Business Development 

ESCAL Consulting United States

Karine Berthier
Associate Partner  

Esquaredasset United States

E Squared Capital is an accomplished fund targeting emerging growth companies with potentially disruptive technologies or services. Founded in 2009, our flexible approach and team of seasoned professionals has particular expertise in finding unique solutions for public and private companies to accelerate growth, and significantly enhance shareholder valuation in a wide array of industries. 

Our strategy includes not only investing our partners' capital, but sourcing capital from third parties. We support out investments with capital market advice and we develop creative solutions for companies seeking financing and operational expertise. These alliances offer unique access for company executives to better build and grow their businesses in an effective, strategic and thoughtful manner.

Mr Les Funtleyder
Portfolio Manager 

Essex Group Int. United States

Mr Anthony Sun

Eutropics United States

Eutropics is advancing personalized medicine by providing novel, predictive diagnostic tests that are uniquely accurate in guiding patient cancer treatments.

» Innovative leading cancer treatment response predictors

» Demonstrated medical utility in blood cancers

» CLIA certified tests for Acute Myeloid Leukemia

» Validated tests for Chronic Lymphocytic Leukemia

Mr Michael Cardone
Co-founder, President and CEO